LBTSF - Almirall and the University of Dundee announce a multi-target research collaboration to develop novel Targeted Protein Degraders medicines
PR Newswire
BARCELONA, Spain, Oct. 8, 2020
BARCELONA, Spain , Oct. 8, 2020 /PRNewswire/ -- Almirall, S.A. (ALM) , a global biopharmaceutical company focused on skin health, and University of Dundee , a top-ranked university in the UK for biological sciences, announced today a research collaboration agreement with the aim to identify and develop a novel class of medicines that target and degrade disease-causing proteins. The collaboration brings together Almirall's strong knowledge in dermatology with the expertise of Professor Alessio Ciulli , one of the pioneers in the field of Targeted Protein Degraders (also known as PROTACs), and his research group at the School of Life Sciences at the University of Dundee . Through this collaboration, Almirall aims at developing drugs for severe skin diseases with high level of unmet medical need.
PROTACs have emerged as a new pharmaceutical modality with the potential to revolutionise drug discovery. They are designed to co-opt the cell's natural disposal system (the ubiquitin-proteasome) to remove disease-driving proteins and are expected to be broadly applicable to diverse therapeutic areas such as immuno-dermatology, onco-dermatology, immunology, oncology, and also respiratory diseases.
The main objective of this collaboration is to identify and develop new compounds on a set of innovative and exclusive biological targets defined by Almirall. " This partnership is an example of how world class university researchers and the pharmaceutical industry can work together to accelerate drug discovery and improve patients' lives by transformative medicines, " said Dr. Thomas Huber , Research Director at Almirall .
Alessio Ciulli, Ph.D., Chair of Chemical Structural Biology at the University of Dundee and winner of the 2015 EFMC Prize for a Young Medicinal Chemist in Academia: " We are looking forward to working on this new research collaboration with Almirall . We are excited to partner with one of the world-leading pharmaceutical companies in the therapeutic area of dermatology, to advance a next-generation of first-in-class degraders as pharmaceutical agents that will eliminate protein drivers of disease to ultimately benefit patients."
The company, founded in 1943 and headquartered in Barcelona , is publically traded on the Spanish Stock Exchange and is a member of the IBEX 35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros .
SOURCE Almirall, S.A.
Company Name: | Almirall Sa Ord |
Stock Symbol: | LBTSF |
Market: | OTC |
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by PR Newswire via Quote Media. Read our full disclaimer.